Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ABVC BioPharma, Inc. (ABVC : NSDQ)

• Company Description    ABVC BioPharma Inc. is a clinical-stage biopharmaceutical company developing botanical-based therapies for central nervous system, ophthalmology and oncology/hematology indications. ABVC BioPharma Inc. is based in SILICON VALLEY, CA. Number of Employees: 19

• Price / Volume Information    Yesterday's Closing Price: $2.85 Daily Weekly Monthly 20 Day Moving Average: 103,211 shares Shares Outstanding: 23.54 (millions) Market Capitalization: $67.09 (millions) Beta: 0.27 52 Week High: $5.48 52 Week Low: $0.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.25% -7.90% 12 Week 46.91% 33.44% Year To Date 383.05% 319.19%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 44370 Old Warm Springs Blvd - Fremont,CA 94538 USA ph: 510-668-0881 fax: - None http://www.abvcpharma.com

• General Corporate Information    Officers Uttam Patil - Chief Executive Officer Eugene Jiang - Chairman of the Board of Directors Uttam Patil - Interim Chief Financial Officer Yen-Hsin Chou - Director Che-Wei Hsu - Director Peer Information ABVC BioPharma, Inc. (CORR.) ABVC BioPharma, Inc. (RSPI) ABVC BioPharma, Inc. (CGXP) ABVC BioPharma, Inc. (BGEN) ABVC BioPharma, Inc. (GTBP) ABVC BioPharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00091F304 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 23.54 Most Recent Split Date: 7.00 (0.10:1) Beta: 0.27 Market Capitalization: $67.09 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.87 Price/Cash Flow: - Price / Sales: 131.82 EPS Growth vs. Year Ago Period: -44.44% vs. Previous Quarter: -116.67% Sales Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -99.49% ROE 06/30/25 - -46.76 03/31/25 - -29.62 12/31/24 - -81.67 ROA 06/30/25 - -23.02 03/31/25 - -14.08 12/31/24 - -38.39 Current Ratio 06/30/25 - 0.42 03/31/25 - 0.22 12/31/24 - 0.33 Quick Ratio 06/30/25 - 0.42 03/31/25 - 0.22 12/31/24 - 0.33 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -963.46 Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -963.46 Pre-Tax Margin 06/30/25 - -1,160.36 03/31/25 - -666.53 12/31/24 - -1,052.94 Book Value 06/30/25 - 0.49 03/31/25 - 0.50 12/31/24 - 0.06 Inventory Turnover 06/30/25 - 0.05 03/31/25 - 0.17 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©